RA Capital Management HCAT Position
Active4-Fund ConvergenceRA Capital Management initiated a new position in Health Catalyst, Inc. (HCAT) in Q4 2025, holding $1.9M worth of shares across 793,749 shares.
HCAT is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for MHS-1031 in 45 days (May 31, 2026), making the timing of RA Capital's position particularly relevant.
Short interest stands at 11.3% of float with 6.7 days to cover, indicating significant bearish positioning against RA Capital's long thesis.
About Health Catalyst, Inc.
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.
Full company profile →Short Interest
11.3%
6.7 days to cover
Frequently Asked Questions
Does RA Capital Management own HCAT?
Yes. As of Q4 2025, RA Capital Management holds 793,749 shares of Health Catalyst, Inc. (HCAT) valued at $1.9M. This data comes from their SEC 13F filing.
How many hedge funds own HCAT?
4 specialist biotech hedge funds currently hold HCAT, including Deerfield Management, Rock Springs Capital, Boxer Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy HCAT?
RA Capital Management's position in HCAT was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's HCAT position increasing or decreasing?
RA Capital Management initiated a new position in HCAT in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
HCATCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →